Celcuity Inc (CELC)

$107.95 +3.46 (3.31%)
Market Cap 5.26B
Revenue (ttm) 0.00
Net Income (ttm) -177.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 2.39
Volume 1,044,300
Avg Vol 1,469,616
Day's Range N/A - N/A
Shares Out 48.77M
Stochastic %K 98%
Beta 0.16
Analysts Strong Sell
Price Target $160.64

Company Profile

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 neg...

Industry: Biotechnology
Sector: Healthcare
Phone: (763) 392-0123
Address:
2800 Campus Drive, Suite 140, Minneapolis, United States
Tetoooo
Tetoooo Jul. 3 at 7:33 PM
$CELC I do not like the fundamental here. Check the full picture for free http://FinPile.ai
1 · Reply
Mikeymer86
Mikeymer86 Jul. 3 at 6:32 PM
$CELC thought this was $CELH and I almost shit my pants
0 · Reply
Oscarca
Oscarca Jul. 3 at 6:13 PM
$CELC It’s going to be one exciting July with both $CELC and $VERA
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jul. 3 at 10:35 AM
$CELC 2% a day makes me
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jul. 2 at 8:29 PM
$CELC omg omg my net worth @GangsterX 
0 · Reply
MZ2X
MZ2X Jul. 2 at 8:08 PM
$CELC great movement today
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jul. 2 at 4:03 PM
$CELC
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jul. 1 at 7:38 PM
$CELC $PRAX $UNCY $.60 more and I’m golden
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jul. 1 at 11:53 AM
$CELC
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jul. 1 at 1:29 AM
$CELC $PRAX $UNCY and thank God I did. UNCY is a fire sale. I predict $5.80 within two weeks.
0 · Reply
Latest News on CELC
Celcuity Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 10, 2026, 8:00 AM EDT - 24 days ago

Celcuity Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Celcuity Slides: FY 2026

Jun 10, 2026, 8:00 AM EDT - 24 days ago

Celcuity Slides: FY 2026

Celcuity Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 1:25 PM EDT - 4 weeks ago

Celcuity Transcript: Jefferies Global Healthcare Conference 2026

Celcuity prices $500M convertible senior note offering

2026-06-04T11:42:59.000Z - 4 weeks ago

Celcuity prices $500M convertible senior note offering

Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032

Jun 3, 2026, 10:13 PM EDT - 4 weeks ago

Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032

Celcuity price target lowered to $171 from $189 at Craig-Hallum

2026-06-03T15:14:03.000Z - 4 weeks ago

Celcuity price target lowered to $171 from $189 at Craig-Hallum

Celcuity price target lowered to $166 from $183 at Wells Fargo

2026-06-03T11:46:12.000Z - 4 weeks ago

Celcuity price target lowered to $166 from $183 at Wells Fargo

Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032

Jun 3, 2026, 7:19 AM EDT - 4 weeks ago

Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032

Celcuity price target lowered to $145 from $185 at H.C. Wainwright

2026-06-03T10:21:27.000Z - 4 weeks ago

Celcuity price target lowered to $145 from $185 at H.C. Wainwright

Celcuity plunges after experimental breast cancer treatment data disappoints

Jun 2, 2026, 1:20 PM EDT - 4 weeks ago

Celcuity plunges after experimental breast cancer treatment data disappoints

Celcuity falls -23.5%

2026-06-02T16:20:25.000Z - 4 weeks ago

Celcuity falls -23.5%

Celcuity falls -22.2%

2026-06-02T16:08:41.000Z - 4 weeks ago

Celcuity falls -22.2%

Celcuity reports efficacy, safety data from PIK3CA mutant cohort of VIKTORIA-1

2026-06-02T14:59:25.000Z - 4 weeks ago

Celcuity reports efficacy, safety data from PIK3CA mutant cohort of VIKTORIA-1

Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer

Jun 2, 2026, 8:25 AM EDT - 4 weeks ago

Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer

Celcuity Transcript: Study result

Jun 2, 2026, 8:00 AM EDT - 4 weeks ago

Celcuity Transcript: Study result

Celcuity Press release: Study result

Jun 2, 2026, 8:00 AM EDT - 4 weeks ago

Celcuity Press release: Study result

Celcuity Slides: Study result

Jun 2, 2026, 8:00 AM EDT - 4 weeks ago

Celcuity Slides: Study result

Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026

Jun 1, 2026, 8:30 AM EDT - 4 weeks ago

Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026

Celcuity To Participate in Upcoming Investor Conferences

May 28, 2026, 8:30 AM EDT - 5 weeks ago

Celcuity To Participate in Upcoming Investor Conferences

Celcuity price target raised to $185 from $165 at H.C. Wainwright

2026-05-18T10:05:06.000Z - 6 weeks ago

Celcuity price target raised to $185 from $165 at H.C. Wainwright

Celcuity price target raised to $175 from $150 at Stifel

2026-05-15T13:21:29.000Z - 7 weeks ago

Celcuity price target raised to $175 from $150 at Stifel

Celcuity price target raised to $183 from $150 at Wells Fargo

2026-05-15T11:00:19.000Z - 7 weeks ago

Celcuity price target raised to $183 from $150 at Wells Fargo

Celcuity reports Q1 adjusted EPS (86c) vs. (81c) last year

2026-05-14T21:44:38.000Z - 7 weeks ago

Celcuity reports Q1 adjusted EPS (86c) vs. (81c) last year

Celcuity Earnings Call Transcript: Q1 2026

May 14, 2026, 4:30 PM EDT - 7 weeks ago

Celcuity Earnings Call Transcript: Q1 2026

Celcuity Earnings release: Q1 2026

May 14, 2026, 4:30 PM EDT - 7 weeks ago

Celcuity Earnings release: Q1 2026

Celcuity Quarterly report: Q1 2026

May 14, 2026, 4:30 PM EDT - 7 weeks ago

Celcuity Quarterly report: Q1 2026

Notable companies reporting after market close

2026-05-14T20:12:10.000Z - 7 weeks ago

Notable companies reporting after market close

AMAT BOOT FIG

Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 4:01 PM EDT - 7 weeks ago

Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update

Celcuity announces amendments to VIKTORIA-2 clinical trial of gedatolisib

2026-05-14T14:18:58.000Z - 7 weeks ago

Celcuity announces amendments to VIKTORIA-2 clinical trial of gedatolisib

Celcuity's Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients

May 14, 2026, 7:30 AM EDT - 7 weeks ago

Celcuity's Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients

Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call

May 7, 2026, 8:00 AM EDT - 2 months ago

Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call

Celcuity rises 18.4%

2026-05-04T16:06:29.000Z - 2 months ago

Celcuity rises 18.4%

Celcuity rises 17.1%

2026-05-04T14:25:21.000Z - 2 months ago

Celcuity rises 17.1%

Celcuity price target raised to $189 from $141 at Craig-Hallum

2026-05-04T13:49:08.000Z - 2 months ago

Celcuity price target raised to $189 from $141 at Craig-Hallum

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

May 1, 2026, 5:03 PM EDT - 2 months ago

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

Celcuity Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Celcuity Proxy statement: Proxy filing

Celcuity Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Celcuity Proxy statement: Proxy filing

Celcuity Earnings Call Transcript: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 3 months ago

Celcuity Earnings Call Transcript: Q4 2025

Celcuity Annual report: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 3 months ago

Celcuity Annual report: Q4 2025

Celcuity Earnings release: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 3 months ago

Celcuity Earnings release: Q4 2025

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 25, 2026, 4:01 PM EDT - 3 months ago

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call

Mar 18, 2026, 8:00 AM EDT - 3 months ago

Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call

Celcuity Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 2:20 PM EDT - 4 months ago

Celcuity Transcript: Leerink Global Healthcare Conference 2026

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology

Mar 9, 2026, 5:42 PM EDT - 4 months ago

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology

Celcuity Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 10:30 AM EST - 4 months ago

Celcuity Transcript: TD Cowen 46th Annual Health Care Conference

Celcuity Appoints Charles Romp to its Board of Directors

Feb 12, 2026, 4:05 PM EST - 5 months ago

Celcuity Appoints Charles Romp to its Board of Directors

Celcuity Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 9:30 AM EST - 5 months ago

Celcuity Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:05 AM EST - 5 months ago

Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026

These 20 stocks are strong choices for momentum investors

Jan 22, 2026, 10:26 AM EST - 5 months ago

These 20 stocks are strong choices for momentum investors

BE COGT FBYD FRGE INBX KOD LITE

Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Jan 20, 2026, 7:30 AM EST - 5 months ago

Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Dec 11, 2025, 2:35 PM EST - 7 months ago

Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Celcuity Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 7:30 AM EST - 7 months ago

Celcuity Transcript: Evercore ISI 8th Annual HealthCONx Conference

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Nov 26, 2025, 4:05 PM EST - 7 months ago

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference

Nov 26, 2025, 7:05 AM EST - 7 months ago

Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference

Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Nov 17, 2025, 4:05 PM EST - 8 months ago

Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Celcuity Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 8 months ago

Celcuity Earnings Call Transcript: Q3 2025

Celcuity Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 8 months ago

Celcuity Quarterly report: Q3 2025

Celcuity Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 8 months ago

Celcuity Earnings release: Q3 2025

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:01 PM EST - 8 months ago

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Celcuity Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 10:00 AM EST - 8 months ago

Celcuity Transcript: Stifel 2025 Healthcare Conference

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

Nov 5, 2025, 7:05 AM EST - 8 months ago

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference

Nov 4, 2025, 7:05 AM EST - 8 months ago

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

Oct 20, 2025, 9:42 AM EDT - 9 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CRMD RANI RAPT

Celcuity Transcript: Study Result

Oct 20, 2025, 8:00 AM EDT - 9 months ago

Celcuity Transcript: Study Result

Celcuity Press release: Study Result

Oct 20, 2025, 8:00 AM EDT - 9 months ago

Celcuity Press release: Study Result

Celcuity Slides: Study Result

Oct 20, 2025, 8:00 AM EDT - 9 months ago

Celcuity Slides: Study Result

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

Oct 18, 2025, 4:30 AM EDT - 9 months ago

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)

Oct 18, 2025, 4:30 AM EDT - 9 months ago

Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

Oct 18, 2025, 4:30 AM EDT - 9 months ago

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

Celcuity Slides: Corporate Presentation

Oct 16, 2025, 7:00 AM EDT - 9 months ago

Celcuity Slides: Corporate Presentation

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

Sep 22, 2025, 9:15 AM EDT - 10 months ago

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

Sep 9, 2025, 4:01 PM EDT - 10 months ago

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program

Aug 27, 2025, 4:05 PM EDT - 11 months ago

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program

Celcuity Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 11 months ago

Celcuity Earnings Call Transcript: Q2 2025

Celcuity Earnings release: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 11 months ago

Celcuity Earnings release: Q2 2025

Celcuity Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 11 months ago

Celcuity Quarterly report: Q2 2025

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 4:01 PM EDT - 11 months ago

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

Aug 7, 2025, 7:05 AM EDT - 11 months ago

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants

Jul 30, 2025, 6:30 AM EDT - 1 year ago

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants

Celcuity: What's Happening With CELC Stock?

Jul 29, 2025, 6:40 AM EDT - 1 year ago

Celcuity: What's Happening With CELC Stock?

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

Jul 28, 2025, 4:02 PM EDT - 1 year ago

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success

Jul 28, 2025, 3:02 PM EDT - 1 year ago

Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success

Celcuity Transcript: Status Update

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Celcuity Transcript: Status Update

Celcuity Slides: Status Update

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Celcuity Slides: Status Update

Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study

Jul 28, 2025, 7:49 AM EDT - 1 year ago

Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

Jul 28, 2025, 7:00 AM EDT - 1 year ago

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

Jul 25, 2025, 4:05 PM EDT - 1 year ago

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Jul 24, 2025, 4:01 PM EDT - 1 year ago

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042

Jul 14, 2025, 7:05 AM EDT - 1 year ago

Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

Jun 30, 2025, 7:05 AM EDT - 1 year ago

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

Celcuity Slides: Corporate Presentation

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Celcuity Slides: Corporate Presentation

Celcuity Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 7:35 AM EDT - 1 year ago

Celcuity Transcript: Jefferies Global Healthcare Conference 2025

Celcuity Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 28, 2025, 9:30 AM EDT - 1 year ago

Celcuity Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

May 21, 2025, 7:05 AM EDT - 1 year ago

Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

Celcuity Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Celcuity Earnings Call Transcript: Q1 2025

Celcuity Earnings release: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Celcuity Earnings release: Q1 2025

Celcuity Quarterly report: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Celcuity Quarterly report: Q1 2025

Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:01 PM EDT - 1 year ago

Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

May 7, 2025, 7:05 AM EDT - 1 year ago

Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

Celcuity Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 10, 2025, 11:00 AM EDT - 1 year ago

Celcuity Transcript: 24th Annual Needham Virtual Healthcare Conference

Celcuity Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 9, 2025, 10:00 AM EDT - 1 year ago

Celcuity Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Celcuity Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Celcuity Proxy statement: Proxy Filing

Celcuity Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Celcuity Proxy statement: Proxy Filing

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Apr 1, 2025, 7:05 AM EDT - 1 year ago

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 4:01 PM EDT - 1 year ago

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Celcuity Earnings Call Transcript: Q4 2024

Mar 31, 2025, 2:00 AM EDT - 1 year ago

Celcuity Earnings Call Transcript: Q4 2024

Celcuity Annual report: Q4 2024

Mar 31, 2025, 2:00 AM EDT - 1 year ago

Celcuity Annual report: Q4 2024

Celcuity Earnings release: Q4 2024

Mar 31, 2025, 2:00 AM EDT - 1 year ago

Celcuity Earnings release: Q4 2024

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call

Mar 24, 2025, 7:05 AM EDT - 1 year ago

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call

Celcuity Transcript: Leerink Global Healthcare Conference 2025

Mar 12, 2025, 9:20 AM EDT - 1 year ago

Celcuity Transcript: Leerink Global Healthcare Conference 2025

Celcuity Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 10:30 AM EST - 1 year ago

Celcuity Transcript: TD Cowen 45th Annual Healthcare Conference

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

Feb 25, 2025, 7:05 AM EST - 1 year ago

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

Tetoooo
Tetoooo Jul. 3 at 7:33 PM
$CELC I do not like the fundamental here. Check the full picture for free http://FinPile.ai
1 · Reply
Mikeymer86
Mikeymer86 Jul. 3 at 6:32 PM
$CELC thought this was $CELH and I almost shit my pants
0 · Reply
Oscarca
Oscarca Jul. 3 at 6:13 PM
$CELC It’s going to be one exciting July with both $CELC and $VERA
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jul. 3 at 10:35 AM
$CELC 2% a day makes me
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jul. 2 at 8:29 PM
$CELC omg omg my net worth @GangsterX 
0 · Reply
MZ2X
MZ2X Jul. 2 at 8:08 PM
$CELC great movement today
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jul. 2 at 4:03 PM
$CELC
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jul. 1 at 7:38 PM
$CELC $PRAX $UNCY $.60 more and I’m golden
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jul. 1 at 11:53 AM
$CELC
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jul. 1 at 1:29 AM
$CELC $PRAX $UNCY and thank God I did. UNCY is a fire sale. I predict $5.80 within two weeks.
0 · Reply
Oscarca
Oscarca Jun. 30 at 6:20 PM
$CELC what do you guys think about a short squeeze potential ?
1 · Reply
Oscarca
Oscarca Jun. 30 at 4:35 PM
$CELC
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jun. 30 at 2:54 PM
$CELC $150INBOUND
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jun. 30 at 11:45 AM
$CELC July 17th babyyyyy up 1000% in the last year babyyyy !!! What’s another couple hundred bucks ? LOAD UP @GangsterX
0 · Reply
JFais
JFais Jun. 29 at 9:24 PM
$FTH another CFO purchase today ($401K.X) + $405K 2 days ago 🧐 (last week's blog post below) Interesting commentary in our Chat re multi-nodal approach being superior $CELC's Geda (may have to set price alerts)
0 · Reply
oneg
oneg Jun. 29 at 6:39 PM
$CELC Grabbed a few more :)
1 · Reply
TheTarkioTrader
TheTarkioTrader Jun. 29 at 3:13 PM
$CELC baby, I am spoiled, but it does not look like it’s trading that great today
1 · Reply
chartistmind
chartistmind Jun. 29 at 1:46 PM
$CELC fam, locking in the 19%+ 🚀 ripper within weeks into the stocktwits records.
0 · Reply
MZ2X
MZ2X Jun. 29 at 1:39 PM
$CELC add morning dips trim midday rinse and repeat. Holding an underlying long position too
0 · Reply
Skoufc1
Skoufc1 Jun. 28 at 11:55 AM
$CELC What do you guys think the probabilty of getting FDA Approval is ? 70%-75%??? Any educated opinions welcome?
3 · Reply
BIOTECH_GURU
BIOTECH_GURU Jun. 28 at 12:40 AM
$CELC $SLS I give em free information. They heckle me every time. Garbage they said. Okie doke I say. We are just gettting started. 5 year highs coming. They will attempt to shake out retail. I will double down. I'M NOT LEAVING.
1 · Reply
chartistmind
chartistmind Jun. 26 at 10:00 PM
$CELC some more 🚀 juice pls for 20% within days.
1 · Reply